Antibodies are the most rapidly growing drug class and have a major impact on human
health, particularly in oncology, autoimmunity and chronic inflammatory diseases. Many of …

Although the therapeutic efficacy and commercial success of monoclonal antibodies (mAbs)
are tremendous, the design and discovery of new candidates remain a time and cost …

It has been over four decades since the development of monoclonal antibodies (mAbs)
using a hybridoma cell line was first reported. Since then more than thirty therapeutic …

Antibodies are proteins that recognize the molecular surfaces of potentially noxious
molecules to mount an adaptive immune response or, in the case of autoimmune diseases …

The elicitation of anti-drug antibodies (ADA) against biotherapeutics can have detrimental
effects on drug safety, efficacy, and pharmacokinetics. The immunogenicity of …

Protein solubility is often an essential requirement in biotechnological and biomedical
applications. Great advances in understanding the principles that determine this specific …

Although it is well known that proteins are only marginally stable in their folded states, it is
often less well appreciated that most proteins are inherently aggregation-prone in their …

Monoclonal antibodies have proved to be a highly successful class of therapeutic products.
Large‐scale manufacturing of pharmaceutical antibodies is a complex activity that requires …

Today, potential immunogenicity can be better evaluated during the drug development
process, and we have rational approaches to manage the clinical consequences of …

The purpose of this work was to construct a consensus prediction algorithm of 'aggregation-
prone'peptides in globular proteins, combining existing tools. This allows comparison of the …